Navigation Links
OncoGenex Pharmaceuticals Added to Russell Indexes
Date:6/30/2009

true opportunity set.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Total returns data for the Russell 3000 and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals Files Shelf Registration Statement
2. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
5. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
6. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
7. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
10. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
11. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 SoundConnect , an ... proud to announce that Darren Suders has joined the ... Darren will drive the partner program through ... , Darren brings more than 10-years of ... roles in channel operations, from policy development, to partner ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 /PRNewswrie/ -- Theravalues ... per il mercato europeo in occasione di Hi Europe ... ). Si tratta della curcumina con ... tecnologia amorfa (senza cristalli) e ingredienti approvati dalle norme ... presente nella spezia della pianta curcumina ( Curcuma longa ...
(Date:11/24/2014)... , Belgium , Nov. 24, 2014 ... sciences company focused on developing diagnostic tests for cancer and ... cancer study will be presented at the Science for Business ... Belgium . The data come from VolitionRx,s ... at the Pneumology department of the Centre Hospitalier Universitaire (CHU) ...
(Date:11/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on the ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
Breaking Biology Technology:SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3
... have been to IT Nirvana, and I like it. , ,OK, ... Rick Dempsey, the VP of IT at Rayovac , it ... IT isnt fighting for respect. They get invited to the table ... Dempsey They arent nearly deaf from the constant ringing of ...
... not alone. Its estimated that more than 100 million Americans (and ... lose weight in 2005. , ,The majority of Americans make a ... of Americans who set a resolution (according to GNC in 2001) ... New Year. Just over 12 months ago, and nearly 50 pounds ...
... you pay to get in, you pay to park your ... the service providers in town. , ,In other words, corporate ... they go? Because theyre tired of fending off all the ... services and bombard them for weeks afterward with follow-up calls ...
Cached Biology Technology:Is Rayovac IT Nirvana? An exclusive interview with Rick Dempsey, VP of IT 2Is Rayovac IT Nirvana? An exclusive interview with Rick Dempsey, VP of IT 3Is Rayovac IT Nirvana? An exclusive interview with Rick Dempsey, VP of IT 4IPod, I Run: The technology of weight loss 2IPod, I Run: The technology of weight loss 3IPod, I Run: The technology of weight loss 4Wake up and smell the networking coffee 2Wake up and smell the networking coffee 3Wake up and smell the networking coffee 4
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... They,re soft, biocompatible, about 7 millimeters long ... "bio-bots" developed at the University of Illinois are ... biological machines has been a riddle that scientists ... struggled to solve. The walking bio-bots demonstrate the ...
... Valley, NY. (Nov. 15, 2012) Two studies published ... (21:7), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , ... a study carried out at Baylor University, researchers concerned ... pancreas preservation and islet isolation have found that low ...
... for BC,s troubled salmon populations A University ... British Columbia,s pink salmon populations, and the salmon farming industry ... from sea lice infestations., There has long been concern that ... to wild fish stock in surrounding waters. , The researchers ...
Cached Biology News:These bots were made for walking: Cells power biological machines 2Studies in Cell Transplantation investigate oxygen's impact as a factor in transplantation 2Studies in Cell Transplantation investigate oxygen's impact as a factor in transplantation 3Researchers uncover some good news for BC's troubled salmon populations 2
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Biology Products: